Gold NanoParticles / GPx Cancer Research Results

GoldNP, Gold NanoParticles: Click to Expand ⟱
Features:
Gold NanoParticles are often used as drug carrier. Has impressive optical properties.
Gold nanoparticles (AuNPs) are best treated as a nanomaterial “platform” (theranostic / drug-delivery / energy-enhancement adjunct) rather than a single drug. In oncology, their value comes from physics + delivery: Au strongly absorbs/scatters light (plasmonics) enabling photothermal tumor heating; it is a high-Z material that can amplify radiation dose deposition (radiosensitization); and it can be engineered (size/shape/surface ligands) to accumulate in tumors and carry payloads (drugs, immune agonists, imaging dyes). The main translation constraints are heterogeneous tumor delivery (EPR variability), biodistribution/clearance (often liver/spleen uptake), and the fact that many impressive in-vitro effects depend on exposure levels not always achieved in human tumors.

Platform : AuNP, Gold NanoParticles
Gold nanoparticles are engineered high-Z nanomaterials used in oncology primarily as (1) photothermal transducers, (2) radiosensitizers, and (3) targeted delivery/theranostic carriers. Effects are strongly dependent on particle size/shape/coating, tumor delivery (EPR/targeting), and whether an external energy source (light, radiation) is applied.

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Tumor delivery & accumulation (EPR + active targeting) Intratumoral AuNP accumulation enables all downstream modalities (PTT/RT/drug delivery); highly variable across tumors RES uptake (liver/spleen) often dominates biodistribution G Delivery constraint / enabler EPR is heterogeneous in humans; size/PEGylation/ligands alter PK, but “more targeting” does not guarantee deep tumor penetration. (EPR reality check is a major translation limiter.)
2 Photothermal conversion (plasmonic heating; NIR-triggered) Local hyperthermia → protein denaturation, membrane damage, vascular disruption → tumor cell death (when illuminated) Off-target heating risk depends on nanoparticle localization + light delivery geometry P, R Energy-to-heat tumor ablation Clinical pilot data exist for prostate focal ablation using gold nanoshell photothermal therapy (example: AuroShell-like approach). Outcome is modality-driven (light + AuNP), not “drug-like.”
3 Radiosensitization (high-Z dose enhancement) Radiation effect ↑ via increased local energy deposition + secondary electrons; can increase tumor kill if AuNPs are in/near tumor cells Normal tissue risk if AuNPs accumulate outside tumor; dose enhancement is spatially local P, R Radiotherapy amplification Most robust when tumor uptake is strong and radiation geometry overlaps AuNP distribution; mechanisms include physical dose enhancement and downstream oxidative/DNA damage amplification.
4 Drug delivery / payload carriage (chemo, siRNA, immune agonists) Higher intratumoral payload concentration; controlled release strategies can improve therapeutic index (context) Carrier uptake by RES can shift toxicity profiles (liver/spleen exposure) R, G Targeted delivery / PK shaping AuNPs are frequently used as “carriers” rather than actives. Translation hinges on reproducible manufacturing, stability, and tumor penetration beyond vasculature.
5 Theranostics (imaging + therapy) CT contrast / photoacoustic / optical tracking to confirm delivery + guide treatment Imaging may reveal off-target uptake and inform safety P, R Localization + monitoring Theranostic value is practical: confirm that nanoparticles actually reached the tumor before applying energy (light/RT) or interpreting response.
6 Tumor microenvironment (TME) remodeling & immune modulation (nanoparticle-tunable) Can alter macrophage polarization, antigen presentation, and T-cell infiltration depending on design/payload; may enhance immunotherapy (context) Systemic immune effects possible; depends on formulation and immune activation strategy G Immunomodulation (platform-dependent) Often not “gold itself,” but gold-as-carrier for immune cues; still, nanoparticle properties can influence TME and immune trafficking.
7 ROS / oxidative stress (secondary; modality-dependent) ROS ↑ can occur after PTT/RT amplification or via surface/catalytic effects; may contribute to apoptosis/necrosis Oxidative stress is a general tissue-injury mechanism if exposure is off-target or excessive P, R Stress amplification ROS is usually a downstream mediator of (a) radiation enhancement or (b) thermal injury/inflammation. It is rarely the primary “intent” unless AuNPs are coupled to photodynamic/ROS-generating systems.
8 Nrf2 / antioxidant response (resistance / protection axis) Nrf2 activation in tumors can blunt ROS-mediated killing (radio/thermal/chemo stress), potentially reducing efficacy in high-Nrf2 tumors Nrf2 is generally protective in normal tissues against oxidative injury G Response modifier Nrf2 is not a primary AuNP mechanism but can explain variable sensitivity: if the therapeutic effect is ROS/stress-mediated, Nrf2-high tumors may be more resistant; in normal tissue Nrf2 is usually a safety buffer.
9 Clearance / persistence (RES uptake; long-term burden) Limits effective tumor dosing if most particles are sequestered; chronic retention is a concern depending on size/coating Liver/spleen accumulation is common; long-term safety depends on formulation and dose G Translation constraint Unlike small molecules, “elimination” can be slow; engineering (size, shape, coating) trades off circulation time vs clearance vs tumor uptake.
10 Clinical evidence status (heterogeneous; indication-specific) Human data exist for specific AuNP modalities (e.g., photothermal nanoshell approaches), but broad claims should be avoided — — Reality check AuNPs are best framed as adjuncts to established modalities (light/RT/drug delivery). Most “pan-cancer” statements fail because delivery, tumor geometry, and modality coupling dominate outcomes.

Time-Scale Flag (TSF): P = 0–30 min (energy deposition / immediate physicochemical effects), R = 30 min–3 hr (acute stress signaling, early injury response), G = >3 hr (immune remodeling, clearance, adaptation/phenotypes).
GPx, Glutathione peroxidases: Click to Expand ⟱
Source:
Type:
Glutathione peroxidases (GPXs) are crucial antioxidant enzymes, counteracting reactive oxygen species (ROS).
Glutathione peroxidase (GPx) refers to a family of antioxidant enzymes that play a crucial role in protecting cells from oxidative stress by catalyzing the reduction of hydrogen peroxide and organic peroxides. There are several isoforms of GPx, including GPx1, GPx2, GPx3, and GPx4, each with distinct tissue distributions and functions.
GPX overexpression promotes proliferation and invasion in cancer cells. Glutathione peroxidase-1 (GPX1), the most abundant isoform, contributes to invasion, migration, cisplatin resistance, and proliferation in various cancers.

GPx expression is often elevated in various cancers and is generally associated with poorer prognosis due to its role in protecting cancer cells from oxidative stress and contributing to treatment resistance.


Scientific Papers found: Click to Expand⟱
1407- GoldNP,  Z,    The antioxidant effects of silver, gold, and zinc oxide nanoparticles on male mice in in vivo condition
- in-vivo, NA, NA
ROS↑, GPx↓, Catalase↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   GPx↓, 1,   ROS↑, 1,  
Total Targets: 3

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: GPx, Glutathione peroxidases
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:180  Target#:418  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page